BRD4 and cancer: Although BRD4 has been recognised as a potential target for cancer therapy,37 none of the BRD4 inhibitors in current clinical trials have received approval from the United States Food and Drug Administration (FDA) for human use due to ‘off‐target’ effects and induced drug resistance.37